Novus Diagnostics

Novus Diagnostics is a Dublin-based medical device company developing ground-breaking point-of-care diagnostics technologies for rapid bedside diagnosis of critical conditions. The company's flagship product, SepTec, is a 15-minute sample-to-answer diagnostic device that detects and characterizes bloodstream infections in whole blood using novel electrochemical sensors, centrifugal microfluidics, and automated sample processing — targeting sepsis, which kills more than 11 million people annually. Founded in 2020, Novus has secured over €7 million in funding from the EU and investors including Trinity Biotech.